Mouse pharmacological models of cognitive disruption relevant to schizophrenia

Neuropharmacology

Volumn 62, Issue 3, 2012, Pages 1381-1390

  Young, Jared W ^a   Powell, Susan B ^a   Geyer, Mark A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Veteran's Administration   (United States)

Author keywords

Amphetamine; Animal models; Attention; Learning; Memory; Mice; Pharmacological; Phencyclidine; Schizophrenia; Scopolamine

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; AMPHETAMINE; ARIPIPRAZOLE; BACLOFEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; CUTAMESINE; DIZOCILPINE; DONEPEZIL; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; GALANTAMINE; HALOPERIDOL; KETAMINE; MINOCYCLINE; NEUROLEPTIC AGENT; PHENCYCLIDINE; PHYSOSTIGMINE; RACLOPRIDE; RISPERIDONE; SCOPOLAMINE;

BEHAVIOR CHANGE; BINDING AFFINITY; BINDING SITE; BRAIN REGION; COGNITIVE DEFECT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EXECUTIVE FUNCTION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LATENT PERIOD; MOLECULAR PATHOLOGY; NONHUMAN; PREDICTIVE VALIDITY; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; SPECIES COMPARISON; SPECIES DIFFERENCE; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MICE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84856113316     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.06.013     Document Type: Review

References (179)

1. K.M. Abel, M.P. Allin, D.R. Hemsley, and M.A. Geyer Low dose ketamine increases prepulse inhibition in healthy men Neuropharmacology 44 2003 729 737 (Pubitemid 36388764)
2. N.C. Andreasen, M. Flaum, S. Schultz, S. Duzyurek, and D. Miller Diagnosis, methodology and subtypes of schizophrenia Neuropsychobiology 35 1997 61 63 (Pubitemid 27117212)
3. S. Arai, K. Takuma, H. Mizoguchi, D. Ibi, T. Nagai, H. Kamei, H.C. Kim, and K. Yamada GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice Eur. J. Pharmacol. 602 2009 101 104
4. P.A. Arguello, and J.A. Gogos Cognition in mouse models of schizophrenia susceptibility genes Schizophr. Bull. 36 2010 289 300
5. D.M. Barch, C.S. Carter, A. Arnsten, R.W. Buchanan, J.D. Cohen, M. Geyer, M.F. Green, J.H. Krystal, K. Nuechterlein, T. Robbins, S. Silverstein, E.E. Smith, M. Strauss, T. Wykes, and R. Heinssen Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting Schizophr. Bull. 35 2009 109 114
6. G.R. Barker, F. Bird, V. Alexander, and E.C. Warburton Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex J. Neurosci. 27 2007 2948 2957 (Pubitemid 46438982)
7. M.M. Behrens, S.S. Ali, and L.L. Dugan Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia J. Neurosci. 28 2008 13957 13966
8. T.S. Benice, and J. Raber Dihydrotestosterone modulates spatial working-memory performance in male mice J. Neurochem. 110 2009 902 911
9. S. Beraki, A. Kuzmin, F. Tai, and S.O. Ogren Repeated low dose of phencyclidine administration impairs spatial learning in mice: blockade by clozapine but not by haloperidol Eur. Neuropsychopharmacol. 18 2008 486 497
10. S. Beraki, R. Diaz-Heijtz, F. Tai, and S.O. Ogren Effects of repeated treatment of phencyclidine on cognition and gene expression in C57BL/6 mice Int. J. Neuropsychopharmacol. 12 2009 243 255
11. G.B. Bissonette, G.J. Martins, T.M. Franz, E.S. Harper, G. Schoenbaum, and E.M. Powell Double dissociation of the effects of medial and orbital prefrontal cortical lesions on attentional and affective shifts in mice J. Neurosci. 28 2008 11124 11130
12. E. Bora, B. Veznedaroglu, and B. Kayahan The effect of galantamine added to clozapine on cognition of five patients with schizophrenia Clin. Neuropharmacol. 28 2005 139 141 (Pubitemid 40923414)
13. P.H. Botton, M.S. Costa, A.P. Ardais, S. Mioranzza, D.O. Souza, J.B. da Rocha, and L.O. Porciuncula Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice Behav. Brain Res. 214 2010 254 259
14. V.P. Bozikas, M.H. Kosmidis, G. Kiosseoglou, and A. Karavatos Neuropsychological profile of cognitively impaired patients with schizophrenia Compr. Psychiatry 47 2006 136 143 (Pubitemid 43259419)
15. D.L. Braff, and M.A. Geyer Sensorimotor gating and schizophrenia. Human and animal model studies Arch. Gen. Psychiatry 47 1990 181 188 (Pubitemid 20058094)
16. J.L. Brigman, T.J. Bussey, L.M. Saksida, and L.A. Rothblat Discrimination of multidimensional visual stimuli by mice: intra- and extradimensional shifts Behav. Neurosci. 119 2005 839 842 (Pubitemid 40934376)
17. J.L. Brigman, J. Ihne, L.M. Saksida, T.J. Bussey, and A. Holmes Effects of subchronic phencyclidine (PCP) treatment on social behaviors, and operant discrimination and reversal learning in C57BL/6J mice Front. Behav. Neurosci. 3 2009 2
18. J.L. Brigman, C. Graybeal, and A. Holmes Predictably irrational: assaying cognitive inflexibility in mouse models of schizophrenia Front. Neurosci. 4 2010
19. J.L. Brigman, P. Mathur, J. Harvey-White, A. Izquierdo, L.M. Saksida, T.J. Bussey, S. Fox, E. Deneris, D.L. Murphy, and A. Holmes Pharmacological or genetic inactivation of the serotonin transporter improves reversal learning in mice Cereb. Cortex 20 2010 1955 1963
20. R.W. Buchanan, A. Summerfelt, C. Tek, and J. Gold An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia Schizophr. Res. 59 2003 29 33 (Pubitemid 35284490)
21. R.W. Buchanan, M. Davis, D. Goff, M.F. Green, R.S. Keefe, A.C. Leon, K.H. Nuechterlein, T. Laughren, R. Levin, E. Stover, W. Fenton, and S.R. Marder A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia Schizophr. Bull. 31 2005 5 19 (Pubitemid 41214353)
22. R.W. Buchanan, R. Freedman, D.C. Javitt, A. Abi-Dargham, and J.A. Lieberman Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia Schizophr. Bull. 33 2007 1120 1130 (Pubitemid 47347922)
23. R.W. Buchanan, R.R. Conley, D. Dickinson, M.P. Ball, S. Feldman, J.M. Gold, and R.P. McMahon Galantamine for the treatment of cognitive impairments in people with schizophrenia Am. J. Psychiatry 165 2008 82 89 (Pubitemid 351704556)
24. T.J. Bussey, L.M. Saksida, and L.A. Rothblat Discrimination of computer-graphic stimuli by mice: a method for the behavioral characterization of transgenic and gene-knockout models Behav. Neurosci. 115 2001 957 960 (Pubitemid 32738343)
25. M. Cannon, and P. Jones Schizophrenia J. Neurol. Neurosurg. Psychiatry 60 1996 604 613 (Pubitemid 26237110)
26. M. Carli, T.W. Robbins, J.L. Evenden, and B.J. Everitt Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal Behav. Brain Res. 9 1983 361 380 (Pubitemid 13002330)
27. C.S. Carter Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia Schizophr. Bull. 31 2005 810 815 (Pubitemid 41437774)
28. C.S. Carter, and D.M. Barch Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative Schizophr. Bull. 33 2007 1131 1137 (Pubitemid 47347921)
29. G. Cassens, A.K. Inglis, P.S. Appelbaum, and T.G. Gutheil Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients Schizophr. Bull. 16 1990 477 499
30. S. Chouinard, E. Stip, J. Poulin, J.P. Melun, R. Godbout, F. Guillem, and H. Cohen Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits Curr. Med. Res. Opin. 23 2007 575 583 (Pubitemid 46456905)
31. Y.S. Chuhan, and H.K. Taukulis Impairment of single-trial memory formation by oral methylphenidate in the rat Neurobiol. Learn. Mem. 85 2006 125 131 (Pubitemid 43247838)
32. B. Crespo-Facorro, J.M. Rodriguez-Sanchez, R. Perez-Iglesias, I. Mata, R. Ayesa, M. Ramirez-Bonilla, O. Martinez-Garcia, and J.L. Vazquez-Barquero Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison J. Clin. Psychiatry 70 2009 717 729
33. J.G. Csernansky, M. Martin, R. Shah, A. Bertchume, J. Colvin, and H. Dong Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice Neuropsychopharmacology 30 2005 2135 2143 (Pubitemid 41643964)
34. R. D'Hooge, and P.P. De Deyn Applications of the Morris water maze in the study of learning and memory Brain Res. Brain Res. Rev. 36 2001 60 90 (Pubitemid 32763130)
35. O.P. Dall'Igna, A.L. Da Silva, M.O. Dietrich, A. Hoffmann, R.V. de Oliveira, D.O. Souza, and D.R. Lara Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-D-aspartate receptor antagonist MK-801 in mice Psychopharmacology (Berl.) 166 2003 258 263 (Pubitemid 36384772)
36. N. de Bruin, and B. Pouzet Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval Pharmacol. Biochem. Behav. 85 2006 253 260 (Pubitemid 44772926)
37. J.P. de Bruin, F. Sanchez-Santed, R.P. Heinsbroek, A. Donker, and P. Postmes A behavioural analysis of rats with damage to the medial prefrontal cortex using the Morris water maze: evidence for behavioural flexibility, but not for impaired spatial navigation Brain Res. 652 1994 323 333 (Pubitemid 24227288)
38. N.M. de Bruin, F. Fransen, H. Duytschaever, C. Grantham, and A.A. Megens Attentional performance of (C57BL/6Jx129Sv)F2 mice in the five-choice serial reaction time task Physiol. Behav. 89 2006 692 703 (Pubitemid 44894253)
39. R.V. de Oliveira, O.P. Dall'Igna, A.B. Tort, J.F. Schuh, P.F. Neto, M.W. Santos Gomes, D.O. Souza, and D.R. Lara Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice Behav. Pharmacol. 16 2005 79 84 (Pubitemid 40477533)
40. D.A. DeSteno, and C. Schmauss Induction of early growth response gene 2 expression in the forebrain of mice performing an attention-set-shifting task Neuroscience 152 2008 417 428
41. E. Dere, Q. Zheng-Fischhofer, D. Viggiano, U.A. Gironi Carnevale, L.A. Ruocco, A. Zlomuzica, M. Schnichels, K. Willecke, J.P. Huston, and A.G. Sadile Connexin31.1 deficiency in the mouse impairs object memory and modulates open-field exploration, acetylcholine esterase levels in the striatum, and cAMP response element-binding protein levels in the striatum and piriform cortex Neuroscience 153 2008 396 405
42. P.E. Dickson, T.D. Rogers, N. Del Mar, L.A. Martin, D. Heck, C.D. Blaha, D. Goldowitz, and G. Mittleman Behavioral flexibility in a mouse model of developmental cerebellar Purkinje cell loss Neurobiol. Learn. Mem. 94 2010 220 228
43. J.C. Dodart, C. Mathis, and A. Ungerer Scopolamine-induced deficits in a two-trial object recognition task in mice Neuroreport 8 1997 1173 1178 (Pubitemid 27198592)
44. A. Egerton, L. Reid, C.E. McKerchar, B.J. Morris, and J.A. Pratt Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia Psychopharmacology (Berl.) 179 2005 77 84 (Pubitemid 40576694)
45. B. Fagerlund, B. Soholm, A. Fink-Jensen, H. Lublin, and B.Y. Glenthoj Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study Clin. Neuropharmacol. 30 2007 3 12 (Pubitemid 46204312)
46. F. Ferreri, C. Agbokou, and S. Gauthier Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy J. Psychiatry Neurosci. 31 2006 369 376 (Pubitemid 44807895)
47. S.B. Floresco, M.A. Geyer, L.H. Gold, and A.A. Grace Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia Schizophr. Bull. 31 2005 888 894 (Pubitemid 41437783)
48. B.S. Folley, R. Astur, K. Jagannathan, V.D. Calhoun, and G.D. Pearlson Anomalous neural circuit function in schizophrenia during a virtual Morris water task Neuroimage 49 2010 3373 3384
49. J.I. Friedman Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists Psychopharmacology (Berl.) 174 2004 45 53 (Pubitemid 38925090)
50. H. Geerts Of mice and men: bridging the translational disconnect in CNS drug discovery CNS Drugs 23 2009 915 926
51. R.T. Gerlai, A. McNamara, S. Williams, and H.S. Phillips Hippocampal dysfunction and behavioral deficit in the water maze in mice: an unresolved issue? Brain Res. Bull. 57 2002 3 9 (Pubitemid 34102978)
52. M.A. Geyer Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? Dialogues Clin. Neurosci. 8 2006 9 16
53. M.A. Geyer New opportunities in the treatment of cognitive impairments associated with schizophrenia Curr. Dir. Psychol. Sci. 19 2010 264 269
54. M.A. Geyer, and A. Markou The role of preclinical models in the development of psychotropic drugs K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff, Neuropsychopharmacology: The Fifth Generation of Progress 2002 Lippincott Williams & Wilkins Philadelphia 445 455
55. M.A. Geyer, and F.X. Vollenweider Serotonin research: contributions to understanding psychoses Trends Pharmacol. Sci. 2008
56. D.E. Gloriam, R. Fredriksson, and H.B. Schioth The G protein-coupled receptor subset of the rat genome BMC Genomics 8 2007 338
57. P. Goetghebeur, and R. Dias Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study Psychopharmacology (Berl.) 202 2009 287 293
58. P.J. Goetghebeur, L. Lerdrup, A. Sylvest, and R. Dias Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model Psychopharmacology (Berl.) 2010
59. F.K. Graham, L.E. Putnam, and L.A. Leavitt Lead-stimulation effects of human cardiac orienting and blink reflexes J. Exp. Psychol. Hum. Percept. Perform. 104 1975 175 182
60. B. Greco, R.W. Invernizzi, and M. Carli Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268 Psychopharmacology (Berl.) 179 2005 68 76 (Pubitemid 40576693)
61. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153 1996 321 330 (Pubitemid 26074706)
62. M.F. Green Cognitive impairment and functional outcome in schizophrenia and bipolar disorder J. Clin. Psychiatry 67 Suppl. 9 2006 3 8 discussion 36-42 (Pubitemid 44369648)
63. M.F. Green, S.R. Marder, S.M. Glynn, S.R. McGurk, W.C. Wirshing, D.A. Wirshing, R.P. Liberman, and J. Mintz The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone Biol. Psychiatry 51 2002 972 978 (Pubitemid 34607714)
64. L. Gutierrez-Galve, C.A. Wheeler-Kingshott, D.R. Altmann, G. Price, E.M. Chu, V.C. Leeson, A. Lobo, G.J. Barker, T.R. Barnes, E.M. Joyce, and M.A. Ron Changes in the frontotemporal cortex and cognitive correlates in first-episode psychosis Biol. Psychiatry 68 2010 51 60
65. A.L. Halberstadt, and M.A. Geyer Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens Neuropharmacology 2011
66. R.S. Hammond, L.E. Tull, and R.W. Stackman On the delay-dependent involvement of the hippocampus in object recognition memory Neurobiol. Learn. Mem. 82 2004 26 34 (Pubitemid 38737427)
67. D.D. Han, and H.H. Gu Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs BMC Pharmacol. 6 2006 6
68. D.K. Hannesson, J.G. Howland, and A.G. Phillips Interaction between perirhinal and medial prefrontal cortex is required for temporal order but not recognition memory for objects in rats J. Neurosci. 24 2004 4596 4604 (Pubitemid 38656615)
69. D.K. Hannesson, G. Vacca, J.G. Howland, and A.G. Phillips Medial prefrontal cortex is involved in spatial temporal order memory but not spatial recognition memory in tests relying on spontaneous exploration in rats Behav. Brain Res. 153 2004 273 285 (Pubitemid 38829310)
70. P.D. Harvey, and R.S. Keefe Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment Am. J. Psychiatry 158 2001 176 184 (Pubitemid 32116511)
71. P.D. Harvey, M.F. Green, S.R. McGurk, and H.Y. Meltzer Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study Psychopharmacology (Berl.) 169 2003 404 411 (Pubitemid 37255530)
72. P.D. Harvey, H. Meltzer, G.M. Simpson, S.G. Potkin, A. Loebel, C. Siu, and S.J. Romano Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia Schizophr. Res. 66 2004 101 113 (Pubitemid 38041108)
73. P.D. Harvey, J. Rabinowitz, M. Eerdekens, and M. Davidson Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial Am. J. Psychiatry 162 2005 1888 1895 (Pubitemid 41428618)
74. K. Hashimoto, Y. Fujita, T. Ishima, H. Hagiwara, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of alpha7 nicotinic receptors Eur. J. Pharmacol. 553 2006 191 195 (Pubitemid 44779614)
75. K. Hashimoto, Y. Fujita, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors Neuropsychopharmacology 32 2007 514 521
76. R.W. Heinrichs Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Arch. Gen. Psychiatry 64 2007 631 632 (Pubitemid 46878664)
77. S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics Am. J. Psychiatry 163 2006 185 194 (Pubitemid 44480836)
78. M. Horiguchi, M. Huang, and H.Y. Meltzer Interaction of mGlu(2/3) agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats Psychopharmacology (Berl.) 2011
79. T. Humby, F.M. Laird, W. Davies, and L.S. Wilkinson Visuospatial attentional functioning in mice: interactions between cholinergic manipulations and genotype Eur. J. Neurosci. 11 1999 2813 2823 (Pubitemid 29364198)
80. N. Idris, J. Neill, B. Grayson, B. Bang-Andersen, L.M. Witten, L.T. Brennum, and J. Arnt Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms Psychopharmacology (Berl.) 208 2010 23 36
81. A. Izquierdo, L.M. Wiedholz, R.A. Millstein, R.J. Yang, T.J. Bussey, L.M. Saksida, and A. Holmes Genetic and dopaminergic modulation of reversal learning in a touchscreen-based operant procedure for mice Behav. Brain Res. 171 2006 181 188 (Pubitemid 43946491)
82. D.C. Javitt Glutamate as a therapeutic target in psychiatric disorders Mol. Psychiatry 9 2004 984 997 979 (Pubitemid 39524288)
83. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am. J. Psychiatry 148 1991 1301 1308
84. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225 (Pubitemid 29067401)
85. J.D. Jentsch, L. Dazzi, J.P. Chhatwal, C.D. Verrico, and R.H. Roth Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats Neurosci. Lett. 258 1998 175 178 (Pubitemid 29023576)
86. D.N. Jones, J.C. Barnes, D.L. Kirkby, and G.A. Higgins Age-associated impairments in a test of attention: evidence for involvement of cholinergic systems J. Neurosci. 15 1995 7282 7292
87. P.B. Jones, T.R. Barnes, L. Davies, G. Dunn, H. Lloyd, K.P. Hayhurst, R.M. Murray, A. Markwick, and S.W. Lewis Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch. Gen. Psychiatry 63 2006 1079 1087 (Pubitemid 44498387)
88. H. Kamei, T. Nagai, H. Nakano, Y. Togan, M. Takayanagi, K. Takahashi, K. Kobayashi, S. Yoshida, K. Maeda, K. Takuma, T. Nabeshima, and K. Yamada Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice Biol. Psychiatry 59 2006 75 84 (Pubitemid 43005238)
89. R.S. Keefe, S.G. Silva, D.O. Perkins, and J.A. Lieberman The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis Schizophr. Bull. 25 1999 201 222 (Pubitemid 29272501)
90. R.S. Keefe, L.J. Seidman, B.K. Christensen, R.M. Hamer, T. Sharma, M.M. Sitskoorn, S.L. Rock, S. Woolson, M. Tohen, G.D. Tollefson, T.M. Sanger, and J.A. Lieberman Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis Biol. Psychiatry 59 2006 97 105 (Pubitemid 43117498)
91. R.S. Keefe, R.M. Bilder, S.M. Davis, P.D. Harvey, B.W. Palmer, J.M. Gold, H.Y. Meltzer, M.F. Green, G. Capuano, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, C.E. Davis, J.K. Hsiao, and J.A. Lieberman Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Arch. Gen. Psychiatry 64 2007 633 647 (Pubitemid 46878665)
92. R.S. Keefe, A.K. Malhotra, H.Y. Meltzer, J.M. Kane, R.W. Buchanan, A. Murthy, M. Sovel, C. Li, and R. Goldman Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial Neuropsychopharmacology 33 2008 1217 1228 (Pubitemid 351521707)
93. R.S. Kern, M.F. Green, B.D. Marshall Jr.; W.C. Wirshing, D. Wirshing, S. McGurk, S.R. Marder, and J. Mintz Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients Biol. Psychiatry 44 1998 726 732 (Pubitemid 28496788)
94. R.S. Kern, M.F. Green, B.D. Marshall Jr.; W.C. Wirshing, D. Wirshing, S.R. McGurk, S.R. Marder, and J. Mintz Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr. Bull. 25 1999 223 232 (Pubitemid 29272502)
95. M.V. King, A.J. Sleight, M.L. Woolley, I.A. Topham, C.A. Marsden, and K.C. Fone 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism Neuropharmacology 47 2004 195 204 (Pubitemid 38824643)
96. U. Klaning Greater occurrence of schizophrenia in dizygotic but not monozygotic twins. Register-based study Br. J. Psychiatry 175 1999 407 409
97. E. Kraepelin Dementia Praecox 1896
98. K. Krebs-Thomson, E.M. Ruiz, V. Masten, M. Buell, and M.A. Geyer The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats Psychopharmacology (Berl.) 189 2006 319 329 (Pubitemid 44772815)
99. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr.; and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214 (Pubitemid 24081509)
100. S. Kunitachi, Y. Fujita, T. Ishima, M. Kohno, M. Horio, Y. Tanibuchi, Y. Shirayama, M. Iyo, and K. Hashimoto Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors Brain Res. 1279 2009 189 196
101. V. Laurent, and J. Podhorna Subchronic phencyclidine treatment impairs performance of C57BL/6 mice in the attentional set-shifting task Behav. Pharmacol. 15 2004 141 148 (Pubitemid 38582280)
102. G. Le Pen, A.J. Grottick, G.A. Higgins, and J.L. Moreau Phencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia Neuropsychopharmacology 28 2003 1799 1809 (Pubitemid 41070845)
103. L. Lecourtier, H.C. Neijt, and P.H. Kelly Habenula lesions cause impaired cognitive performance in rats: implications for schizophrenia Eur. J. Neurosci. 19 2004 2551 2560 (Pubitemid 38621852)
104. B.J. Lee, J.G. Lee, and Y.H. Kim A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia J. Psychopharmacol. 21 2007 421 427
105. E.D. Levin, F.J. McClernon, and A.H. Rezvani Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization Psychopharmacology (Berl.) 184 2006 523 539 (Pubitemid 43255869)
106. S.W. Lewis, T.R. Barnes, L. Davies, R.M. Murray, G. Dunn, K.P. Hayhurst, A. Markwick, H. Lloyd, and P.B. Jones Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia Schizophr. Bull. 32 2006 715 723 (Pubitemid 44412859)
107. J.A. Lieberman, J.A. Javitch, and H. Moore Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry Am. J. Psychiatry 165 2008 931 936
108. P. Liu, and D.K. Bilkey The effects of NMDA lesions centered on the postrhinal cortex on spatial memory tasks in the rat Behav. Neurosci. 116 2002 860 873
109. M. Loos, J. Staal, A.N. Schoffelmeer, A.B. Smit, S. Spijker, and T. Pattij Inhibitory control and response latency differences between C57BL/6J and DBA/2J mice in a Go/No-Go and 5-choice serial reaction time task and strain-specific responsivity to amphetamine Behav. Brain Res. 214 2010 216 224
110. A.K. Malhotra, D.A. Pinals, H. Weingartner, K. Sirocco, C.D. Missar, D. Pickar, and A. Breier NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers Neuropsychopharmacology 14 1996 301 307 (Pubitemid 26151927)
111. A.K. Malhotra, C.M. Adler, S.D. Kennison, I. Elman, D. Pickar, and A. Breier Clozapine blunts N-methyl-d-aspartate antagonist-induced psychosis: a study with ketamine Biol. Psychiatry 42 1997 664 668 (Pubitemid 27444500)
112. A.K. Malhotra, D.A. Pinals, C.M. Adler, I. Elman, A. Clifton, D. Pickar, and A. Breier Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics Neuropsychopharmacology 17 1997 141 150 (Pubitemid 27365955)
113. S. Mandillo, A. Rinaldi, A. Oliverio, and A. Mele Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits Behav. Pharmacol. 14 2003 533 544 (Pubitemid 38293514)
114. S.R. Marder The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia Dialogues Clin. Neurosci. 8 2006 109 113
115. S.R. Marder, and W. Fenton Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia Schizophr. Res. 72 2004 5 9 (Pubitemid 39452900)
116. A. Markou, C. Chiamulera, M.A. Geyer, M. Tricklebank, and T. Steckler Removing obstacles in neuroscience drug discovery: the future path for animal models Neuropsychopharmacology 2008
117. L.F. Martin, W.R. Kem, and R. Freedman Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia Psychopharmacology (Berl.) 174 2004 54 64 (Pubitemid 38925091)
118. V. Martinez, and M. Sarter Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia Neuropsychopharmacology 33 2008 2635 2647
119. D. Mazeh, H. Zemishlani, Y. Barak, I. Mirecki, and D. Paleacu Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study Int. Psychogeriatr. 18 2006 429 436 (Pubitemid 44128317)
120. S.L. McLean, B. Grayson, M. Harris, C. Protheroe, S. Bate, M.L. Woolley, and J.C. Neill Isolation rearing impairs novel object recognition and attentional set shifting performance in female rats J. Psychopharmacol. 24 2010 57 63
121. E. Mendelsohn, M. Rosenthal, Y. Bohiri, E. Werber, M. Kotler, and R.D. Strous Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living Int. Clin. Psychopharmacol. 19 2004 319 324 (Pubitemid 39506985)
122. J.M. Meyer, H.A. Nasrallah, J.P. McEvoy, D.C. Goff, S.M. Davis, M. Chakos, J.K. Patel, R.S. Keefe, T.S. Stroup, and J.A. Lieberman The clinical antipsychotic trials of Intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome Schizophr. Res. 80 2005 9 18 (Pubitemid 41587459)
123. J. Mintz, and A. Kopelowicz CUtLASS confirms CATIE Arch. Gen. Psychiatry 64 978 2007 979 980 author reply
124. A.L. Mishara, and T.E. Goldberg A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book Biol. Psychiatry 55 2004 1013 1022 (Pubitemid 38581917)
125. H. Mizoguchi, K. Takuma, A. Fukakusa, Y. Ito, A. Nakatani, D. Ibi, H.C. Kim, and K. Yamada Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice Psychopharmacology (Berl.) 196 2008 233 241
126. H. Moore The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy Schizophr. Bull. 36 2010 1066 1072
127. K. Mori, Y. Obara, T. Moriya, S. Inatomi, and N. Nakahata Effects of Hericium erinaceus on amyloid beta(25-35) peptide-induced learning and memory deficits in mice Biomed. Res. 32 2011 67 72
128. R.G. Morris, P. Garrud, J.N. Rawlins, and J. O'Keefe Place navigation impaired in rats with hippocampal lesions Nature 297 1982 681 683 (Pubitemid 12096189)
129. T. Nagai, R. Murai, K. Matsui, H. Kamei, Y. Noda, H. Furukawa, and T. Nabeshima Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors Psychopharmacology (Berl.) 202 2009 315 328
130. J.C. Neill, S. Barnes, S. Cook, B. Grayson, N.F. Idris, S.L. McLean, S. Snigdha, L. Rajagopal, and M.K. Harte Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism Pharmacol. Ther. 2010
131. K. Niimi, E. Takahashi, and C. Itakura Improved short-term memory and increased expression of NR2B observed in senescence-accelerated mouse (SAM) P6 Exp. Gerontol. 43 2008 847 852
132. Y. Noda, A. Mouri, Y. Ando, Y. Waki, S.N. Yamada, A. Yoshimi, K. Yamada, N. Ozaki, D. Wang, and T. Nabeshima Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems Int. J. Neuropsychopharmacol. 13 2010 1343 1354
133. W.A. Nolen, R.W. Kupka, G. Hellemann, M.A. Frye, L.L. Altshuler, G.S. Leverich, T. Suppes, P.E. Keck Jr.; S. McElroy, H. Grunze, J. Mintz, and R.M. Post Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study Acta Psychiatr. Scand. 115 2007 360 365 (Pubitemid 46570066)
134. B. Oranje, C.C. Gispen-de Wied, M.N. Verbaten, and R.S. Kahn Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol Biol. Psychiatry 52 2002 887 895 (Pubitemid 35223432)
135. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov,
136. T. Pattij, M.C. Janssen, M. Loos, A.B. Smit, A.N. Schoffelmeer, and M.M. van Gaalen Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains Genes Brain Behav. 6 2007 579 587 (Pubitemid 47246223)
137. J.S. Paulsen, N. Butters, J.R. Sadek, S.A. Johnson, D.P. Salmon, N.R. Swerdlow, and M.R. Swenson Distinct cognitive profiles of cortical and subcortical dementia in advanced illness Neurology 45 1995 951 956
138. G.D. Pearlson Neurobiology of schizophrenia Ann. Neurol. 48 2000 556 566
139. S.B. Powell, M.A. Geyer, M.A. Preece, L.K. Pitcher, G.P. Reynolds, and N.R. Swerdlow Dopamine depletion of the nucleus accumbens reverses isolation-induced deficits in prepulse inhibition in rats Neuroscience 119 2003 233 240 (Pubitemid 36577426)
140. S.B. Powell, X. Zhou, and M.A. Geyer Prepulse inhibition and genetic mouse models of schizophrenia Behav. Brain Res. 204 2009 282 294
141. S.E. Purdon, A. Malla, A. Labelle, and W. Lit Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol J. Psychiatry Neurosci. 26 2001 137 149 (Pubitemid 32373127)
142. R.J. Radek, K.L. Kohlhaas, L.E. Rueter, and E.G. Mohler Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists Curr. Pharm. Des. 16 2010 309 322
143. R.J. Ralph, and S.B. Caine Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice J. Pharmacol. Exp. Ther. 312 2005 733 741 (Pubitemid 40189573)
144. R.J. Ralph-Williams, V. Lehmann-Masten, V. Otero-Corchon, M.J. Low, and M.A. Geyer Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice J. Neurosci. 22 2002 9604 9611 (Pubitemid 35356202)
145. R.J. Ralph-Williams, V. Lehmann-Masten, and M.A. Geyer Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice Neuropsychopharmacology 28 2003 108 118
146. S.R. Ribeiz, D.P. Bassitt, J.A. Arrais, R. Avila, D.C. Steffens, and C.M. Bottino Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature CNS Drugs 24 2010 303 317
147. E. Richelson, and T. Souder Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds Life Sci. 68 2000 29 39
148. S.C. Risch, M.D. Horner, S.R. McGurk, S. Palecko, J.S. Markowitz, Z. Nahas, and C.L. DeVane Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study Schizophr. Res. 93 2007 131 135 (Pubitemid 46817923)
149. T.W. Robbins The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry Psychopharmacology (Berl.) 163 2002 362 380
150. J.S. Rodefer, E.R. Murphy, and M.G. Baxter PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats Eur. J. Neurosci. 21 2005 1070 1076 (Pubitemid 40461058)
151. J.D. Rollnik, M. Borsutzky, T.J. Huber, H. Mogk, J. Seifert, H.M. Emrich, and U. Schneider Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics Neuropsychobiology 45 2002 74 80 (Pubitemid 34224981)
152. K.A. Sacco, C. Creeden, E.L. Reutenauer, and T.P. George Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia Schizophr. Res. 103 2008 326 327
153. M. Sarter Animal cognition: defining the issues Neurosci. Biobehav. Rev. 28 2004 645 650 (Pubitemid 39535862)
154. M. Sarter Preclinical research into cognition enhancers Trends Pharmacol. Sci. 27 2006 602 608 (Pubitemid 44572394)
155. E. Scarr, and B. Dean Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J. Neurochem. 107 2008 1188 1195
156. M.H. Schubert, K.A. Young, and P.B. Hicks Galantamine improves cognition in schizophrenic patients stabilized on risperidone Biol. Psychiatry 60 2006 530 533 (Pubitemid 44402376)
157. T. Sharma, C. Reed, I. Aasen, and V. Kumari Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation Schizophr. Res. 85 2006 73 83 (Pubitemid 43947524)
158. J.M. Silvers, S.B. Harrod, C.F. Mactutus, and R.M. Booze Automation of the novel object recognition task for use in adolescent rats J. Neurosci. Methods 166 2007 99 103 (Pubitemid 47374810)
159. P. Singer, J. Feldon, and B.K. Yee Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice Psychopharmacology (Berl.) 206 2009 677 698
160. R.C. Smith, J. Warner-Cohen, M. Matute, E. Butler, E. Kelly, S. Vaidhyanathaswamy, and A. Khan Effects of nicotine nasal spray on cognitive function in schizophrenia Neuropsychopharmacology 31 2006 637 643 (Pubitemid 43276979)
161. H.E. Spohn, and M.E. Strauss Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia J. Abnorm Psychol. 98 1989 367 380 (Pubitemid 20066209)
162. K.E. Stevens, R. Freedman, A.C. Collins, M. Hall, S. Leonard, M.J. Marks, and G.M. Rose Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains Neuropsychopharmacology 15 1996 152 162 (Pubitemid 26255162)
163. R. Stryjer, R.D. Strous, F. Bar, E. Werber, G. Shaked, Y. Buhiri, M. Kotler, A. Weizman, and J.M. Rabey Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia Clin. Neuropharmacol. 26 2003 12 17 (Pubitemid 36184110)
164. A.V. Terry Jr. Role of the central cholinergic system in the therapeutics of schizophrenia Curr. Neuropharmacol. 6 2008 286 292
165. M.S. Thomsen, D.Z. Christensen, H.H. Hansen, J.P. Redrobe, and J.D. Mikkelsen alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment Neuropharmacology 56 2009 1001 1009
166. J. van Os, and P. McGuffin Can the social environment cause schizophrenia? Br. J. Psychiatry 182 2003 291 292 (Pubitemid 36408278)
167. D.I. Velligan, J. Newcomer, J. Pultz, J. Csernansky, A.L. Hoff, R. Mahurin, and A.L. Miller Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr. Res. 53 2002 239 248 (Pubitemid 34008588)
168. D.I. Velligan, T.J. Prihoda, D. Sui, J.L. Ritch, N. Maples, and A.L. Miller The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings J. Clin. Psychiatry 64 2003 524 531 (Pubitemid 36618280)
169. D. Wang, Y. Noda, Y. Zhou, A. Nitta, H. Furukawa, and T. Nabeshima Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model Neuropharmacology 52 2007 1179 1187
170. K.A. Waters, K.E. Burnham, D. O'Connor, G.R. Dawson, and R. Dias Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat J. Psychopharmacol. 19 2005 149 158 (Pubitemid 40577219)
171. G. Weniger, and E. Irle Allocentric memory impaired and egocentric memory intact as assessed by virtual reality in recent-onset schizophrenia Schizophr. Res. 101 2008 201 209
172. M. Wietrzych, H. Meziane, A. Sutter, N. Ghyselinck, P.F. Chapman, P. Chambon, and W. Krezel Working memory deficits in retinoid X receptor gamma-deficient mice Learn. Mem. 12 2005 318 326 (Pubitemid 40958343)
173. D.G. Wilkinson, P.T. Francis, E. Schwam, and J. Payne-Parrish Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy Drugs Aging 21 2004 453 478 (Pubitemid 38736890)
174. B.D. Winters, S.E. Forwood, R.A. Cowell, L.M. Saksida, and T.J. Bussey Double dissociation between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe J. Neurosci. 24 2004 5901 5908 (Pubitemid 38859387)
175. M. Yamada, M. Hayashida, Q. Zhao, N. Shibahara, K. Tanaka, T. Miyata, and K. Matsumoto Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice J. Ethnopharmacol. 2011
176. B.K. Yee Cytotoxic lesion of the medial prefrontal cortex abolishes the partial reinforcement extinction effect, attenuates prepulse inhibition of the acoustic startle reflex and induces transient hyperlocomotion, while sparing spontaneous object recognition memory in the rat Neuroscience 95 2000 675 689
177. J.W. Young, M.A. Geyer, and Subcommittee, P. Report on Putative Preclinical Models of the MATRICS Battery 2007 http://www.turns.ucla.edu/ preclinical-TURNS-report-2006b.pdf
178. J.W. Young, S.B. Powell, V. Risbrough, H.M. Marston, and M.A. Geyer Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia Pharmacol. Ther. 122 2009 150 202
179. J.W. Young, S.B. Powell, M.A. Geyer, D.V. Jeste, and V.B. Risbrough The mouse attentional set-shifting task: a method for assaying successful cognitive aging? Cogn. Affect. Behav. Neurosci. 10 2010 243 251